PMVP Stock Price, PMV Pharmaceuticals, . Quote, Chart

Market Summary

USD1.76-0.01

Delayedas of 30 Apr 2024, 10:58 am

-0.56%

PMVP Alerts

JPMORGAN CHASE & CO reported owning 0% of PMVP [2024-04-09]

PMVP Stock Price

View Fullscreen

PMVP RSI Chart

PMVP Valuation

Market Cap

91.1M

Price/Earnings (Trailing)

-1.32

EV/EBITDA

-0.94

Price/Free Cashflow

-1.61

MarketCap/EBT

-1.32

PMVP Price/Earnings (Trailing)

PMVP Profitability

Return on Equity

-30.56%

Return on Assets

-27.35%

Free Cashflow Yield

-62.18%

PMVP Fundamentals

PMVP Earnings

Earnings (TTM)

-69.0M

Earnings Growth (Yr)

18.55%

Earnings Growth (Qtr)

5.31%

Breaking Down PMVP Revenue

52 Week Range

1.739.72

(Low)(High)

Last 7 days

2.3%

Last 30 days

4.1%

Last 90 days

-2.2%

Trailing 12 Months

-61.6%

How does PMVP drawdown profile look like?

PMVP Financial Health

Current Ratio

14.78

PMVP Investor Care

Shares Dilution (1Y)

12.39%

Diluted EPS (TTM)

-1.45

Tracking the Latest Insider Buys and Sells of PMV Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 18, 2024	carulli michael	acquired	-	-	82,220	chief financial officer
Jan 18, 2024	jalota deepika	acquired	-	-	95,555	chief development officer
Jan 18, 2024	mack david henry	acquired	-	-	163,890	president and ceo
Nov 22, 2023	orbimed advisors llc	sold	-195,763	2.23	-87,786	-
Nov 10, 2023	mack david henry	gifted	-	-	85,307	president and ceo
Nov 10, 2023	mack david henry	gifted	-	-	-85,307	president and ceo
Oct 18, 2023	mack david henry	acquired	105,156	0.53	198,407	president and ceo
Sep 15, 2023	jalota deepika	sold	-27,168	6.62	-4,104	chief development officer
Sep 15, 2023	alland leila	sold	-41,646	6.62	-6,291	chief medical officer
Aug 07, 2023	mack david henry	acquired	45,315	0.53	85,500	president and ceo

Which funds bought or sold PMVP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	added	106	2,000	17,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-6.68	-189,938	199,072	-%
Apr 24, 2024	Assenagon Asset Management S.A.	unchanged	-	-99,139	120,384	-%
Apr 24, 2024	BML Capital Management, LLC	new	-	2,221,030	2,221,030	1.47%
Apr 23, 2024	AMALGAMATED BANK	reduced	-62.72	-9,000	2,000	-%
Apr 23, 2024	FISHMAN JAY A LTD/MI	added	166	43,000	136,000	0.01%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-135,964	-	-%
Apr 19, 2024	DENALI ADVISORS LLC	sold off	-100	-105,090	-	-%
Apr 19, 2024	Cutler Group LLC / CA	unchanged	-	-3,000	4,000	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%

Are Funds Buying or Selling PMVP?

Are funds buying PMVP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PMVP

No. of Funds

PMVP Alerts

JPMORGAN CHASE & CO reported owning 0% of PMVP [2024-04-09]

Unveiling PMV Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	jpmorgan chase & co	0.0%	15,573	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	0%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2024	arrowmark colorado holdings llc	5.31%	2,714,143	SC 13G
Feb 14, 2024	boxer capital, llc	0%	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	2.2%	6	SC 13G/A
Feb 13, 2024	vanguard group inc	4.70%	2,405,307	SC 13G/A
Jan 29, 2024	blackrock inc.	6.3%	3,229,797	SC 13G/A
Jan 23, 2024	state street corp	1.41%	723,454	SC 13G/A
Jan 23, 2024	jpmorgan chase & co	7.1%	3,674,814	SC 13G/A

Recent SEC filings of PMV Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 09, 2024	SC 13G/A	Major Ownership Report
Feb 29, 2024	10-K	Annual Report
Feb 29, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to PMV Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

PMV Pharmaceuticals, Inc. News

Latest updates

PMV Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-3.4%	252	261	242	254	270	285	301	315	332	344	356	354	366	374	103
Current Assets	1.0%	207	205	190	233	247	265	282	288	301	314	323	335	365	374	102
Cash Equivalents	-27.6%	38.00	52.00	68.00	143	108	100	87.00	116	172	177	189	209	361	373	73.00
Net PPE	-1.4%	11.00	11.00	11.00	11.00	11.00	10.00	9.00	5.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	13.0%	26.00	23.00	24.00	24.00	24.00	24.00	24.00	23.00	23.00	19.00	18.00	6.00	6.00	5.00	5.00
Current Liabilities	30.9%	14.00	11.00	11.00	11.00	11.00	12.00	11.00	12.00	12.00	9.00	8.00	6.00	6.00	5.00	5.00
Shareholder's Equity	-5.0%	226	238	218	230	246	261	277	292	309	325	338	348	359	369	-
Retained Earnings	-5.4%	-310	-294	-277	-260	-241	-221	-203	-186	-167	-149	-134	-121	-109	-99.43	-75.44
Additional Paid-In Capital	0.6%	535	532	496	490	488	484	481	479	476	474	472	470	469	468	5.00
Shares Outstanding	0.6%	51.00	51.00	46.00	46.00	46.00	46.00	46.00	45.00	45.00	45.00	45.00	45.00	-	-	-
Float	-	-	-	209	-	-	-	543	-	-	-	1,229	-	1,920	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	22.8%	-12,085	-15,659	-12,901	-15,012	-15,324	-16,759	-13,679	-17,998	-12,028	-12,398	-9,241	-12,904	-10,312	-7,393	-6,896	-8,138	-	-	-
Share Based Compensation	-10.8%	2,966	3,324	3,153	2,932	3,052	2,448	2,518	2,177	1,767	1,796	1,150	627	584	670	383	296	-	-	-
Cashflow From Investing	92.3%	-2,588	-33,639	-63,963	49,645	23,223	29,513	-15,279	-38,825	7,559	-693	-10,553	-139,897	-57.00	8,037	26,315	-6,384	-	-	-
Cashflow From Financing	-99.1%	288	33,146	2,131	12.00	548	6.00	276	128	295	309	1,256	162	-1,359	294,455	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PMVP Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 55,885	$ 51,988	$ 36,493
General and administrative	24,247	25,052	21,800
Total operating expenses	80,132	77,040	58,293
Loss from operations	(80,132)	(77,040)	(58,293)
Other income:
Interest income, net	11,171	3,627	449
Other income (expense), net	3	87	21
Total other income (expense)	11,174	3,714	470
Loss before provision (benefit) for income taxes	(68,958)	(73,326)	(57,823)
Provision (benefit) for income taxes	2	(9)	23
Net loss	(68,960)	(73,317)	(57,846)
Unrealized gain (loss) on available for sale investments, net of tax	635	(367)	(78)
Foreign currency translation gain	34
Total other comprehensive income (loss)	669	(367)	(78)
Total Comprehensive loss	$ (68,291)	$ (73,684)	$ (57,924)
Net loss per share - basic	$ (1.44)	$ (1.61)	$ (1.28)
Net loss per share - diluted	$ (1.44)	$ (1.61)	$ (1.28)
Weighted-average common shares outstanding - basic	48,014,645	45,594,824	45,137,656
Weighted-average common shares outstanding - diluted	48,014,645	45,594,824	45,137,656

PMVP Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 37,706	$ 108,297
Restricted cash	822	822
Marketable securities, current	165,351	132,757
Prepaid expenses and other current assets	3,530	5,130
Total current assets	207,409	247,006
Property and equipment, net	10,666	10,955
Marketable securities, noncurrent	25,505	2,495
Right-of-use assets	8,382	9,539
Other assets	190	313
Total assets	252,152	270,308
Current liabilities:
Accounts payable	3,237	2,996
Accrued expenses	9,940	7,308
Operating lease liability, current	852	528
Total current liabilities	14,029	10,832
Operating lease liabilities, noncurrent	12,434	13,448
Total liabilities	26,463	24,280
Stockholders' equity:
Preferred stock, $0.00001 par value, 5,000,000 shares authorized as of December 31, 2023 and December 31, 2022. No shares issued or outstanding as of December 31, 2023 and December 31, 2022.
Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 51,445,862 and 45,771,332 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively.
Additional paid-in capital	535,468	487,516
Accumulated deficit	(310,003)	(241,043)
Accumulated other comprehensive income (loss)	224	(445)
Total stockholders' equity	225,689	246,028
Total liabilities and stockholders’ equity	$ 252,152	$ 270,308

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing Wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q, and R282W, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

CEO	Dr. David H. Mack Ph.D.
WEBSITE	pmvpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	62

PMV Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for PMV Pharmaceuticals, Inc.? What does PMVP stand for in stocks?

PMVP is the stock ticker symbol of PMV Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PMV Pharmaceuticals, Inc. (PMVP)?

As of Mon Apr 29 2024, market cap of PMV Pharmaceuticals, Inc. is 91.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PMVP stock?

You can check PMVP's fair value in chart for subscribers.

What is the fair value of PMVP stock?

You can check PMVP's fair value in chart for subscribers. The fair value of PMV Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PMV Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PMVP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PMV Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether PMVP is over valued or under valued. Whether PMV Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact PMV Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PMVP.